CN101511372B - 包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物 - Google Patents

包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物 Download PDF

Info

Publication number
CN101511372B
CN101511372B CN2007800324155A CN200780032415A CN101511372B CN 101511372 B CN101511372 B CN 101511372B CN 2007800324155 A CN2007800324155 A CN 2007800324155A CN 200780032415 A CN200780032415 A CN 200780032415A CN 101511372 B CN101511372 B CN 101511372B
Authority
CN
China
Prior art keywords
pharmaceutical composition
cancer
container
group
sulfasalazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800324155A
Other languages
English (en)
Chinese (zh)
Other versions
CN101511372A (zh
Inventor
什姆埃尔·A·本-萨松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tiltan Pharma Ltd
Original Assignee
Tiltan Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiltan Pharma Ltd filed Critical Tiltan Pharma Ltd
Publication of CN101511372A publication Critical patent/CN101511372A/zh
Application granted granted Critical
Publication of CN101511372B publication Critical patent/CN101511372B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2007800324155A 2006-07-07 2007-07-04 包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物 Expired - Fee Related CN101511372B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81916406P 2006-07-07 2006-07-07
US60/819,164 2006-07-07
US88010707P 2007-01-12 2007-01-12
US60/880,107 2007-01-12
PCT/IL2007/000836 WO2008004231A1 (en) 2006-07-07 2007-07-04 Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent

Publications (2)

Publication Number Publication Date
CN101511372A CN101511372A (zh) 2009-08-19
CN101511372B true CN101511372B (zh) 2011-11-16

Family

ID=38519759

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800324155A Expired - Fee Related CN101511372B (zh) 2006-07-07 2007-07-04 包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物

Country Status (8)

Country Link
US (1) US7838513B2 (enExample)
EP (1) EP2043659B1 (enExample)
JP (1) JP2009542623A (enExample)
CN (1) CN101511372B (enExample)
AU (1) AU2007270686B2 (enExample)
CA (1) CA2656910C (enExample)
ES (1) ES2414708T3 (enExample)
WO (1) WO2008004231A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2851079A1 (en) 2005-04-15 2006-10-26 Albert Einstein College Of Medicine Of Yeshiva University Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
EP2043685B1 (en) 2006-07-03 2015-12-23 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
EP2364140A1 (en) * 2008-11-28 2011-09-14 Advance Holdings Limited Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US20140228423A1 (en) * 2011-06-01 2014-08-14 Baylor College Of Medicine Biomarkers and therapy for cancer
CN104144701A (zh) * 2012-01-09 2014-11-12 蒂尔坦制药有限公司 用于治疗癌症的组合疗法
CN105792823B (zh) * 2013-11-01 2019-11-12 皮特尼制药股份有限公司 治疗恶性肿瘤的药物组合
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
WO2016166761A1 (en) * 2015-04-14 2016-10-20 Tiltan Pharma Ltd. Combination therapies and uses thereof in the treatment of cancer
WO2018069924A1 (en) 2016-10-10 2018-04-19 Tiltan Pharma Ltd. Non-cytotoxic combination therapies and uses thereof in the treatment of cancer
TR201717134A2 (tr) * 2016-12-07 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı Ve Enflamasyonun Hızlı Tedavisi İçin Diklofenak Ve H2 Reseptör Antagonistlerinin Çabuk Salımlı Oral Kombinasyonları
TR201718099A2 (tr) * 2017-11-16 2019-06-21 Mehmet Nevzat Pisak Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584001B1 (en) * 1992-08-03 1997-05-14 Bristol-Myers Squibb Company Use of taxol for the manufacture of a medicament for the treatment of cancer
US6268156B1 (en) * 1997-09-23 2001-07-31 Smithkline Beecham Seiyaku K.K. Cancer treatments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128103C (en) * 1992-01-16 2004-12-28 Kapil Mehta Formulation and use of carotenoids in treatment of cancer
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20030158118A1 (en) 2001-11-26 2003-08-21 Weidner Morten Sloth Combination of cimetidine and cysteine derivatives for treating cancer
WO2003061566A2 (en) 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20090010887A1 (en) 2004-10-06 2009-01-08 Ben-Sasson Shmuel A Method and composition for enhancing anti-angiogenic therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584001B1 (en) * 1992-08-03 1997-05-14 Bristol-Myers Squibb Company Use of taxol for the manufacture of a medicament for the treatment of cancer
US6268156B1 (en) * 1997-09-23 2001-07-31 Smithkline Beecham Seiyaku K.K. Cancer treatments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.P.DuVy et al.Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-steroidal Anti-inflammatory Drugs(NSAIDs).《European Journal of Cancer》.1998,第34卷(第8期),1250-1259. *

Also Published As

Publication number Publication date
ES2414708T3 (es) 2013-07-22
EP2043659B1 (en) 2013-04-03
AU2007270686A1 (en) 2008-01-10
AU2007270686B2 (en) 2011-05-26
US20090318391A1 (en) 2009-12-24
CN101511372A (zh) 2009-08-19
CA2656910C (en) 2012-08-28
EP2043659A1 (en) 2009-04-08
JP2009542623A (ja) 2009-12-03
WO2008004231A1 (en) 2008-01-10
CA2656910A1 (en) 2008-01-10
US7838513B2 (en) 2010-11-23

Similar Documents

Publication Publication Date Title
CN101511372B (zh) 包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物
ES2762250T5 (es) Tratamiento combinado del cáncer
ES2201296T3 (es) Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
KR102615210B1 (ko) 난소암의 치료에 사용되는 티노스타무스틴
EP1247524B1 (en) Composition comprising taurolidine and/or taurultam for the treatment of cancer
EP2846638A1 (en) Glufosfamide combination therapies for cancer
KR101563069B1 (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
Balducci et al. Palliative care in older patients with cancer
US20090010887A1 (en) Method and composition for enhancing anti-angiogenic therapy
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
Massaro Liposomal bupivacaine: A long-acting local anesthetic for postsurgical analgesia.
WO2016166761A1 (en) Combination therapies and uses thereof in the treatment of cancer
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
Yeom et al. The application of electrochemotherapy in three dogs with inoperable cancers
AU2001251336B2 (en) Methods and compositions for treating neoplasms
AU2013208649B2 (en) Combination therapy for the treatment of cancer
IL196381A (en) Anti-cancer therapeutic composition and kit comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
WO2018069924A1 (en) Non-cytotoxic combination therapies and uses thereof in the treatment of cancer
ES2295575T3 (es) Combinaciones que comprenden un derivado de epotilona y una imidazotetrazinona.
JP2002524481A5 (enExample)
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111116

Termination date: 20170704

CF01 Termination of patent right due to non-payment of annual fee